About Src kinase-associated phosphoprotein 2
Src kinase-associated phosphoprotein 2 (SKAP2) is a protein
from Homo sapiens identified by UniProt accession
O75563, 359 residues long.
MolForge cross-references it against 0 known binders and
171 disease associations.
Target properties
| Protein name | Src kinase-associated phosphoprotein 2 |
|---|
| UniProt accession | O75563 |
|---|
| Gene | SKAP2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 359 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (171)
Diseases linked to this target (Open Targets).
- type 1 diabetes mellitus · score 0.32
- body mass index · score 0.31
- eosinophil count · score 0.30
- Crohn's disease · score 0.29
- psoriasis · score 0.26
- FEV/FVC ratio · score 0.23
- lymphocyte count · score 0.23
- eosinophil percentage of leukocytes · score 0.22
- ulcerative colitis · score 0.22
- sclerosing cholangitis · score 0.22
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O75563-F1 | alphafold | PREDICTED | 73.97 | — |
Amino-acid sequence (359 residues)
MPNPSSTSSP YPLPEEIRNL LADVETFVAD ILKGENLSKK AKEKRESLIK KIKDVKSIYL QEFQDKGDAE DGEEYDDPFA GPPDTISLAS ERYDKDDEAP SDGAQFPPIA AQDLPFVLKA GYLEKRRKDH SFLGFEWQKR WCALSKTVFY YYGSDKDKQQ KGEFAIDGYS VRMNNTLRKD GKKDCCFEIS APDKRIYQFT AASPKDAEEW VQQLKFVLQD MESDIIPEDY DERGELYDDV DHPLPISNPL TSSQPIDDEI YEELPEEEED SAPVKVEEQR KMSQDSVHHT SGDKSTDYAN FYQGLWDCTG AFSDELSFKR GDVIYILSKE YNRYGWWVGE MKGAIGLVPK AYIMEMYDI
Explore Src kinase-associated phosphoprotein 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets